⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12324 | 0.79 | NCF1 (0.34) | — | |
| SCHEMBL14022395 | 0.79 | NCF1 (0.34) | — | |
| SCHEMBL24008864 | 0.78 | — | — | |
| SCHEMBL13085828 | 0.76 | — | — | |
| SCHEMBL8320328 | 0.76 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL25040749 | 0.76 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL25041101 | 0.76 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL24158560 | 0.75 | — | — | |
| SCHEMBL20715341 | 0.74 | — | — | |
| SCHEMBL20609902 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024118887-A1 | N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023125707-A1 | P38 MAPK/MK2 PATHWAY REGULATOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
| WO-2008143729-A2 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008143730-A2 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008106226-A2 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106204-A1 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X-PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106224-A1 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| EP-1643998-B1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007025284-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |